A phase 2, randomised, double-blind, placebo-controlled trial that assessed change in % predicted FVC at 52 weeks of the anti–IL-13/IL-4 SAR156597 in 325 patients with IPF showed no significant difference in the primary efficacy endpoint [28]. This evidence concerns the gene IL4 and idiopathic pulmonary fibrosis.